TL;DR
This systematic review and meta-analysis compares whole pelvic radiotherapy (WPRT) with prostate-only radiotherapy (PORT) for localized prostate cancer. It found that WPRT significantly improves survival outcomes like biochemical failure-free survival (BFFS) and progression-free survival (PFS), but at the cost of increased gastrointestinal (GI) toxicity.
What Problem Does This Paper Address?
Prostate cancer is a significant health concern, and radiotherapy is a primary treatment. However, there's been ongoing debate about the optimal radiation target volume: should it encompass only the prostate (PORT) or also the surrounding pelvic lymph nodes (WPRT)? While WPRT theoretically offers better control by targeting potential microscopic spread, it also carries a higher risk of side effects. Existing clinical trials have yielded conflicting results, creating a need for a comprehensive analysis to clarify the trade-offs between efficacy and toxicity. This paper aims to resolve this by systematically reviewing and meta-analyzing available evidence.
Methods
The researchers conducted a systematic literature search across major databases (Cochrane, PubMed, Embase, Medline, ClinicalTrials.gov) to identify relevant clinical studies. They included randomized controlled trials (RCTs) and cohort studies (CS) that compared WPRT with PORT for localized prostate cancer and reported on specific survival outcomes (BFFS, PFS, distant metastasis-free survival (DMFS), overall survival (OS)) and toxicities (gastrointestinal (GI) and genitourinary (GU)). Data extraction and quality assessment were performed by two independent investigators. A meta-analysis was conducted to quantify the effect of WPRT versus PORT using hazard ratios (HRs) for survival and risk ratios (RRs) for toxicity, with 95% confidence intervals (CIs). Heterogeneity was assessed using the Chi-squared test and I² statistic, with random-effects models used when significant heterogeneity was present. Subgroup analyses were performed to explore the impact of factors like prior radical prostatectomy (RP), androgen deprivation therapy (ADT), radiation dose, and radiotherapy technology.
Datasets
The study did not introduce new datasets. Instead, it synthesized data from 16 previously published studies that met the inclusion criteria. These studies comprised 6 randomized controlled trials (RCTs) and 10 cohort studies (CS), involving a total of 10,212 participants.
Key Insights and Ideas
- WPRT offers a survival advantage: The most significant finding is that WPRT demonstrably improves key survival metrics compared to PORT. This suggests that targeting pelvic lymph nodes, even in localized disease, can impact long-term outcomes.
- Toxicity is the trade-off: The benefit of WPRT comes with a clear increase in GI toxicity, both acute and late. This highlights the critical need for careful patient selection and management to mitigate these side effects.
- Subgroup differences matter: The impact of WPRT isn't uniform. For patients who haven't had a prostatectomy, WPRT shows a better DMFS. However, higher radiation doses (>49 Gy) in non-RP patients, while improving PFS, also significantly increase GU toxicity.
- RP status is a key differentiator: The benefit of WPRT on survival appears to be consistent regardless of whether patients have undergone radical prostatectomy, but the toxicity profile might differ.
Key Results
- Improved Survival: WPRT significantly improved 5-year BFFS (HR 0.56, CI 0.48–0.66) and PFS (HR 0.82, CI 0.72–0.94) compared to PORT.
- DMFS Benefit (Non-RP): For patients who did not undergo RP, WPRT showed a better 5-year DMFS (HR 0.35, CI 0.15–0.82).
- No OS Difference: Overall survival (OS) did not show a significant difference between WPRT and PORT.
- Increased GI Toxicity: WPRT significantly increased both acute (RR 1.75, CI 1.41–2.18 for non-RP; RR 1.76, CI 1.40–2.22 for RP) and late (RR 2.19, CI 1.47–3.27 for non-RP) GI toxicity.
- GU Toxicity: Acute and late GU toxicity did not show a statistically significant difference overall, but subgroup analysis revealed increased GU toxicity with higher radiation doses (>49 Gy) in non-RP patients.
Limitations and Future Work
The authors acknowledge several limitations:
- Study-Level Subgroup Analyses: Subgroup analyses were based on data aggregated at the study level, which can be less precise than individual patient data.
- Follow-up Duration: The meta-analysis relied on studies with a median follow-up of around 5 years. Longer follow-up (over 10 years) is needed to fully assess the long-term impact on "harder clinical end-points" like cancer-specific survival.
- Limited Evidence for Certain Scenarios: While the study provides valuable insights, there's still a lack of level 1 evidence for specific scenarios, such as the optimal treatment strategy after prostatectomy.
Future work should focus on longer-term follow-up studies to better understand the late effects and survival outcomes. Further research into optimizing WPRT techniques to minimize toxicity while maximizing efficacy is also warranted.
Summary updated